{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T07:42:45Z","timestamp":1784619765873,"version":"3.55.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1097\/mop.0b013e3282f161f2","type":"journal-article","created":{"date-parts":[[2009,3,5]],"date-time":"2009-03-05T01:45:47Z","timestamp":1236217547000},"page":"628-635","source":"Crossref","is-referenced-by-count":53,"title":["Enzyme reconstitution\/replacement therapy for lysosomal storage diseases"],"prefix":"10.1097","volume":"19","author":[{"given":"T Andrew","family":"Burrow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Hopkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy D","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley T","family":"Tinkle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory A","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-5-20210206","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1146\/annurev.bi.61.070192.001515","article-title":"Structure and function of the mannose 6-phosphate\/insulin like growth factor II receptors","volume":"61","author":"Kornfeld","year":"1992","journal-title":"Annu Rev Biochem"},{"key":"R2-5-20210206","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/BF00219337","article-title":"Quantitative correlation between the residual activity of beta-hexosaminidase A and arylsulfatase A and the severity of the resulting lysosomal storage disease","volume":"88","author":"Leinekugel","year":"1992","journal-title":"Hum Genet"},{"key":"R5-5-20210206","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM199105233242104","article-title":"Replacement therapy for inherited enzyme deficiency \u2013 macrophage-targeted glucocerebrosidase for Gaucher's disease","volume":"324","author":"Barton","year":"1991","journal-title":"N Engl J Med"},{"key":"R6-5-20210206","doi-asserted-by":"crossref","first-page":"33","DOI":"10.7326\/0003-4819-122-1-199501010-00005","article-title":"Enzyme therapy in Gaucher disease type 1: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources","volume":"122","author":"Grabowski","year":"1995","journal-title":"Ann Intern Med"},{"issue":"4 Suppl 5","key":"R7-5-20210206","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.seminhematol.2004.07.009","article-title":"Therapeutic goals in the treatment of Gaucher disease","volume":"41","author":"Pastores","year":"2004","journal-title":"Semin Hematol"},{"key":"R8-5-20210206","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1399-0004.2007.00769.x","article-title":"The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease","volume":"71","author":"Charrow","year":"2007","journal-title":"Clin Genet"},{"key":"R9-5-20210206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1359\/jbmr.061004","article-title":"Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease","volume":"22","author":"Wenstrup","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"5 Suppl","key":"R11-5-20210206","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","article-title":"Fabry disease in childhood","volume":"144","author":"Desnick","year":"2004","journal-title":"J Pediatr"},{"key":"R12-5-20210206","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s00431-003-1299-3","article-title":"The early clinical phenotype of Fabry disease: a study on 35 European children and adolescents","volume":"162","author":"Ries","year":"2003","journal-title":"Eur J Pediatr"},{"key":"R13-5-20210206","first-page":"7","article-title":"Fetal pathology in Fabry's disease and mucopolysaccharidosis type I","volume":"34","author":"Elleder","year":"1998","journal-title":"Cesk Patol"},{"key":"R14-5-20210206","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1542\/peds.2005-2895","article-title":"Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease","volume":"118","author":"Ries","year":"2006","journal-title":"Pediatrics"},{"key":"R15-5-20210206","doi-asserted-by":"crossref","first-page":"e344","DOI":"10.1542\/peds.2004-1678","article-title":"Pediatric Fabry disease","volume":"115","author":"Ries","year":"2005","journal-title":"Pediatrics"},{"key":"R16-5-20210206","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1080\/08035250500275022","article-title":"Clinical manifestations of Fabry disease in children: data from the Fabry Outcome Survey","volume":"95","author":"Ramaswami","year":"2006","journal-title":"Acta Paediatr"},{"key":"R17-5-20210206","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1111\/j.1651-2227.2007.00029.x","article-title":"Enzyme replacement therapy with agalsidase alfa in children with Fabry disease","volume":"96","author":"Ramaswami","year":"2007","journal-title":"Acta Paediatr"},{"key":"R18-5-20210206","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1365-2362.2004.01309.x","article-title":"Fabry disease defined: baseline clinical manifestations of 366 patients in the Fabry Outcome Survey","volume":"34","author":"Mehta","year":"2004","journal-title":"Eur J Clin Invest"},{"key":"R19-5-20210206","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1007\/s10545-007-0521-2","article-title":"Fabry disease: baseline medical characteristics of a cohort of 1765 males and females in the Fabry Registry","volume":"30","author":"Eng","year":"2007","journal-title":"J Inherit Metab Dis"},{"key":"R20-5-20210206","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1651-2227.2007.00216.x","article-title":"Gastrointestinal symptoms in Fabry disease: everything is possible, including treatment","volume":"96","author":"Hoffmann","year":"2007","journal-title":"Acta Paediatr Suppl"},{"key":"R21-5-20210206","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/bjo.2006.100602","article-title":"Ocular manifestations of Fabry's disease: data from the Fabry Outcome Survey","volume":"91","author":"Sodi","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R24-5-20210206","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1097\/01.gim.0000237866.70357.c6","article-title":"Fabry disease: guidelines for the evaluation and management of multiorgan system involvement","volume":"8","author":"Eng","year":"2006","journal-title":"Genet Med"},{"key":"R25-5-20210206","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1016\/j.ehj.2003.09.017","article-title":"Gadolinium enhanced cardiovascular magnetic resonance in Anderson\u2013Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium","volume":"24","author":"Moon","year":"2003","journal-title":"Eur Heart J"},{"key":"R26-5-20210206","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1016\/S0140-6736(05)67635-0","article-title":"Prevalence of Fabry disease in patients with cryptogenic stroke: a prospective study","volume":"366","author":"Rolfs","year":"2005","journal-title":"Lancet"},{"key":"R27-5-20210206","doi-asserted-by":"crossref","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","article-title":"Agalsidase-beta therapy for advanced Fabry disease: a randomized trial","volume":"146","author":"Banikazemi","year":"2007","journal-title":"Ann Intern Med"},{"key":"R28-5-20210206","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1073\/pnas.0611315104","article-title":"Proteomics of specific treatment-related alterations in Fabry disease: a strategy to identify biological abnormalities","volume":"104","author":"Moore","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R29-5-20210206","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ymgme.2005.04.009","article-title":"Gastrointestinal manifestations of Fabry disease: clinical response to enzyme replacement therapy","volume":"85","author":"Banikazemi","year":"2005","journal-title":"Mol Genet Metab"},{"key":"R30-5-20210206","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"R31-5-20210206","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of nonclassic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J Neurol"},{"key":"R32-5-20210206","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"R33-5-20210206","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1172\/JCI1722","article-title":"Clinical and metabolic correction of pompe disease by enzyme therapy in acid maltase-deficient quail","volume":"101","author":"Kikuchi","year":"1998","journal-title":"J Clin Invest"},{"issue":"Suppl 1","key":"R34-5-20210206","doi-asserted-by":"crossref","first-page":"S106","DOI":"10.1007\/s00431-002-1015-8","article-title":"Enzyme therapy for Pompe disease: from science to industrial enterprise","volume":"161","author":"Reuser","year":"2002","journal-title":"Eur J Pediatr"},{"key":"R35-5-20210206","first-page":"132","article-title":"Recombinant human acid alpha-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I\/II clinical trial","volume":"3","author":"Amalfitano","year":"2001","journal-title":"Genet Med"},{"key":"R36-5-20210206","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jpeds.2006.02.035","article-title":"Chinese hamster ovary cell-derived recombinant human acid alpha-glucosidase in infantile-onset Pompe disease","volume":"149","author":"Kishnani","year":"2006","journal-title":"J Pediatr"},{"key":"R37-5-20210206","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"Van den Hout","year":"2004","journal-title":"Pediatrics"},{"key":"R38-5-20210206","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"R39-5-20210206","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1460-9592.2004.01242.x","article-title":"Anaesthetic management of infants with glycogen storage disease type II: a physiological approach","volume":"14","author":"Ing","year":"2004","journal-title":"Paediatr Anaesth"},{"key":"R40-5-20210206","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/j.ymthe.2006.08.009","article-title":"Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease","volume":"14","author":"Fukuda","year":"2006","journal-title":"Mol Ther"},{"key":"R41-5-20210206","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre and posttreatment pathology after enzyme replacement therapy for Pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab Invest"},{"key":"R42-5-20210206","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/adc.76.2.92","article-title":"Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres","volume":"76","author":"Vellodi","year":"1997","journal-title":"Arch Dis Child"},{"key":"R43-5-20210206","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1182\/blood.V91.7.2601","article-title":"Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group","volume":"91","author":"Peters","year":"1998","journal-title":"Blood"},{"key":"R44-5-20210206","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3476(98)70201-X","article-title":"Follow-up of nine patients with Hurler syndrome after bone marrow transplantation","volume":"133","author":"Guffon","year":"1998","journal-title":"J Pediatr"},{"key":"R45-5-20210206","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/sj.bmt.1704115","article-title":"Life-threatening pulmonary hemorrhages post bone marrow transplantation in Hurler syndrome. Report of three cases and review of the literature","volume":"32","author":"Gassas","year":"2003","journal-title":"Bone Marrow Transplant"},{"key":"R46-5-20210206","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1056\/NEJM200101183440304","article-title":"Enzyme-replacement therapy in mucopolysaccharidosis I","volume":"344","author":"Kakkis","year":"2001","journal-title":"N Engl J Med"},{"key":"R47-5-20210206","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jpeds.2004.01.046","article-title":"Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase)","volume":"144","author":"Wraith","year":"2004","journal-title":"J Pediatr"},{"key":"R48-5-20210206","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ymgme.2006.08.007","article-title":"A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years","volume":"90","author":"Sifuentes","year":"2007","journal-title":"Mol Genet Metab"},{"key":"R49-5-20210206","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1038\/sj.bmt.1702398","article-title":"Hematopoietic cell transplantation for mucopolysaccharidosis IIB (Hunter syndrome)","volume":"25","author":"Peters","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"R50-5-20210206","first-page":"359","article-title":"Stem cell bone marrow transplantation in patients with metabolic storage diseases","volume":"49","author":"Krivit","year":"2002","journal-title":"Adv Pediatr"},{"key":"R51-5-20210206","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/01.gim.0000232477.37660.fb","article-title":"A phase II\/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome)","volume":"8","author":"Muenzer","year":"2006","journal-title":"Genet Med"},{"key":"R52-5-20210206","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1056\/NEJM198412203112504","article-title":"Bone-marrow transplantation in the Maroteaux\u2013Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation","volume":"311","author":"Krivit","year":"1984","journal-title":"N Engl J Med"},{"key":"R53-5-20210206","first-page":"47","article-title":"Maroteaux\u2013Lamy syndrome (mucopolysaccharidosis type VI). Treatment by allogenic bone marrow transplantation in 6 patients and potential for autotransplantation bone marrow gene insertion","volume":"7","author":"Krivit","year":"1992","journal-title":"Int Pediatr"},{"key":"R54-5-20210206","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1542\/peds.2006-2184","article-title":"Management guidelines for mucopolysaccharidosis VI","volume":"120","author":"Giugliani","year":"2007","journal-title":"Pediatrics"},{"key":"R55-5-20210206","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jpeds.2005.12.014","article-title":"Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study","volume":"148","author":"Harmatz","year":"2006","journal-title":"J Pediatr"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0b013e3282f161f2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:36:50Z","timestamp":1620963410000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-200712000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2007]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0b013e3282f161f2","relation":{},"ISSN":["1040-8703"],"issn-type":[{"value":"1040-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}